The clinical impact of the first‐trimester nuchal translucency between the 95th–99th percentiles
Prenatal Diagnosis · 2023
DOI: 10.1002/pd.6390 ↗Kurz gefasst
Fachartikel in der Zeitschrift Prenatal Diagnosis, 2023. Verfasst von Ilaria Fantasia und 12 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Fetal Medicine and Prenatal Diagnosis, Institute for Maternal and Child Health, IRCCS "Burlo Garofolo", Trieste, Italy. Hauptthemen laut MEDLINE: Nuchal Translucency Measurement, Chromosome Aberrations. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Institute for Maternal and Child Health IRCCS Burlo Garofolo.
Abstract (Originalsprache)
Objectives
To evaluate the clinical significance of nuchal translucency (NT) between the 95th–99th percentile in terms of typical and atypical chromosomal abnormalities (ACAs), associated fetal congenital defects and postnatal outcome.
Methods
A retrospective cohort study of fetuses with NT between the 95th–99th percentile. Data regarding the rate of associated fetal defects, genetic abnormalities and postnatal outcome were collected.
Results
A total of 306 cases of fetuses with an NT between the 95th–99th percentiles were included. The overall rate of genetic abnormalities was 12.1% (37/306). Chromosomal abnormalities were found in 10.1% (31/306) of cases and 2% were ACA (6/306). Within this group, two were pathogenic Copy Number Variants (CNVs) and four were single gene disorders. The overall rate of fetal congenital defects was 13.7% (42/306). All ACAs were found in fetuses with congenital defects. Postnatally, a new diagnosis of a single gene disorder was made in 0.85% of cases (2/236).
Conclusions
The presence of an NT between the 95th–99th percentiles carries a 10‐fold increased risk of fetal defects, representing an indication for referral for a detailed fetal anatomy evaluation. The risk of ACA is mainly related to the presence of fetal defects, irrespective of the combined test risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Unit of Fetal Medicine and Prenatal Diagnosis, Institute for Maternal and Child Health, IRCCS "Burlo Garofolo", Trieste, Italy.
- Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
- Clinical Epidemiology and Public Health Research Unit, Institute for Maternal and Child Health, IRCCS "Burlo Garofolo", Trieste, Italy.
- Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy.
- Department of Genetics, Institute for Maternal and Child Health, IRCCS "Burlo Garofolo", Trieste, Italy.
ORCID-Profile: Ilaria Fantasia
Förderung
- Institute for Maternal and Child Health IRCCS Burlo Garofolo
Zitieren
APA
Fantasia, I., Catagini, S., Zamagni, G., Greco, P., Bianchini, I., Bussolaro, S., Quadrifoglio, M., Lo Bello, L., Monasta, L., Ricci, G., Faletra, F., Feresin, A., & Stampalija, T. (2023). The clinical impact of the first‐trimester nuchal translucency between the 95th–99th percentiles. Prenatal Diagnosis. https://doi.org/10.1002/pd.6390
Vancouver
Fantasia I, Catagini S, Zamagni G, Greco P, Bianchini I, Bussolaro S, et al. The clinical impact of the first‐trimester nuchal translucency between the 95th–99th percentiles. Prenatal Diagnosis. 2023. doi:10.1002/pd.6390
BibTeX
@article{Fantasia2023,
author = {Fantasia, Ilaria and Catagini, Silvia and Zamagni, Giulia and Greco, Pantaleo and Bianchini, Irene and Bussolaro, Sofia and Quadrifoglio, Mariachiara and Lo Bello, Leila and Monasta, Lorenzo and Ricci, Giuseppe and Faletra, Flavio and Feresin, Agnese and Stampalija, Tamara},
title = {The clinical impact of the first‐trimester nuchal translucency between the 95th–99th percentiles},
journal = {Prenatal Diagnosis},
year = {2023},
doi = {10.1002/pd.6390}
}
EUVIMED